A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

Wednesday, June 19, 2024

Dr. Minal Barve

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 22-09

ASCO 2024 Poster for Trial 22-09